How to Get Compound Tirzepatide in 2026: The Five-Step Protocol from Eligibility to First Dose

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded tirzepatide requires a prescription from a licensed provider, obtained through telehealth or in-person consultation after meeting BMI and medical history criteria
• The medication ships from FDA-registered 503B compounding pharmacies, not traditional retail pharmacies, with typical delivery in 5 to 10 business days
• Total monthly cost ranges from $299 to $499 depending on dose and platform, compared to $1,060+ for brand-name Zepbound or Mounjaro
• You cannot get compounded tirzepatide if you have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2

Direct answer (40-60 words)

Getting compounded tirzepatide requires five steps: verify eligibility (BMI 27+ with comorbidity or BMI 30+), complete a telehealth or in-person consultation with a licensed provider, receive a prescription, select a compounding pharmacy, and receive the medication by mail. The entire process takes 3 to 10 days from initial consultation to first dose.

Table of contents

1. What most articles get wrong about compounded tirzepatide access
2. The eligibility requirements: who qualifies and who doesn't
3. Step 1: Choose your access pathway (telehealth vs in-person)
4. Step 2: Complete the medical consultation and screening
5. Step 3: Receive your prescription and understand what it contains
6. Step 4: Pharmacy selection and what to verify before ordering
7. Step 5: Delivery, storage, and preparing your first dose
8. The cost structure: what you'll actually pay in 2026
9. Insurance coverage and why it usually doesn't apply
10. The FDA shortage context and when compounding is legal
11. State-specific restrictions and where access is limited
12. When you should NOT pursue compounded tirzepatide
13. FAQ

What most articles get wrong about compounded tirzepatide access

The most common error in published content about accessing compounded tirzepatide is the claim that "anyone can get it online with a quick questionnaire." This misrepresents both the legal requirements and the clinical screening process.

Compounded tirzepatide is a prescription medication. Federal law (21 USC 353a) requires a valid patient-provider relationship before a prescription can be issued. A "quick questionnaire" alone does not establish that relationship. The provider must review medical history, assess contraindications, and make an individualized clinical determination that the medication is appropriate.

Platforms that advertise "no video visit required" are relying on state-specific allowances for asynchronous telehealth, where a provider reviews written intake forms and may follow up by message or phone. This is legal in most states but still requires substantive clinical review, not rubber-stamping.

The second common error is conflating compounded tirzepatide with research peptides sold by non-pharmacy vendors. Research peptide suppliers sell tirzepatide analogs labeled "not for human consumption" to bypass prescription requirements. These products are not pharmacy-compounded, not subject to sterility testing, and not legal for human use. The FDA issued warning letters to 14 such suppliers in 2023 and 2024 (FDA Enforcement Reports, 2023-2024).

If a website sells tirzepatide without requiring a prescription, it is operating illegally. The product is either mislabeled research peptide or counterfeit medication.

The eligibility requirements: who qualifies and who doesn't

Compounded tirzepatide prescribing follows the same clinical criteria as brand-name Zepbound and Mounjaro. The FDA-approved indications are:

For weight management (Zepbound indication):

• BMI 30 or greater, OR
• BMI 27 or greater with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease)

For type 2 diabetes (Mounjaro indication):

• Diagnosed type 2 diabetes
• Inadequate glycemic control on current therapy or as first-line treatment
• No BMI minimum

Most telehealth platforms use the weight-management criteria because the patient population is larger. Providers have discretion to prescribe off-label for patients slightly below BMI 27 if clinical judgment supports it, but most platforms set hard cutoffs at BMI 27 to reduce liability.

Absolute contraindications (you cannot get tirzepatide):

• Personal history of medullary thyroid carcinoma (MTC)
• Family history of MTC
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Known hypersensitivity to tirzepatide or any excipient
• Pregnancy or breastfeeding

Relative contraindications (requires provider discussion):

• History of pancreatitis
• Severe gastroparesis
• Active gallbladder disease
• Diabetic retinopathy (tirzepatide may worsen retinopathy during rapid glucose reduction)
• Chronic kidney disease stage 4 or 5 (limited safety data)
• History of suicidal ideation (GLP-1 medications carry an FDA monitoring requirement as of 2024)

Age requirements vary by platform. Most require patients to be 18 to 75 years old. Tirzepatide is not FDA-approved for pediatric use, though off-label prescribing for adolescents 12 to 17 with severe obesity is increasing (Kelly et al., Pediatrics, 2024).

Step 1: Choose your access pathway (telehealth vs in-person)

You have three pathways to obtain a compounded tirzepatide prescription:

Pathway A: Telehealth platforms (FormBlends, others)

• Fully remote process
• Intake questionnaire, asynchronous or synchronous video consultation
• Prescription sent directly to affiliated compounding pharmacy
• Medication ships to your home
• Monthly subscription model in most cases
• Typical timeline: 3 to 7 days from signup to first dose

Pathway B: In-person provider

• Schedule appointment with your primary care physician, endocrinologist, or obesity medicine specialist
• In-person exam and history
• Provider writes prescription, you select pharmacy
• You coordinate shipment or pickup
• Typical timeline: 1 to 3 weeks depending on appointment availability

Pathway C: Hybrid (local provider + telehealth pharmacy)

• See your local provider for prescription
• Use the prescription with a telehealth compounding pharmacy for fulfillment
• Less common because most compounding pharmacies require the prescribing provider to have a relationship with the pharmacy

The telehealth pathway is faster and often cheaper because platforms negotiate bulk pricing with compounding pharmacies. The in-person pathway gives you continuity with a provider who knows your full medical history.

Step 2: Complete the medical consultation and screening

The consultation process varies by pathway but includes the same core elements:

Medical history intake:

• Current medications and supplements
• Allergies
• Past medical history (thyroid disease, pancreatitis, gallbladder disease, kidney disease, psychiatric history)
• Family history of MTC or MEN 2
• Surgical history, particularly bariatric surgery
• Current weight, height, BMI
• Weight-loss history and prior attempts

Symptom screening:

• Current GI symptoms (nausea, vomiting, diarrhea, constipation, reflux)
• Diabetic symptoms if applicable (polyuria, polydipsia, neuropathy)
• Cardiovascular symptoms (chest pain, shortness of breath, edema)

Lab review (if recent labs available):

• Hemoglobin A1c (for diabetic patients)
• Lipid panel
• Comprehensive metabolic panel (kidney and liver function)
• Thyroid function tests

Most telehealth platforms do not require labs before the first prescription. Labs become relevant at 3 to 6 months to monitor metabolic response. In-person providers are more likely to order baseline labs.

The consultation itself: For synchronous telehealth (video visit), expect a 10 to 20 minute appointment. The provider will review your intake, confirm contraindications, explain the medication mechanism, discuss side effects, and answer questions.

For asynchronous telehealth, the provider reviews your written intake within 24 to 48 hours. If additional information is needed, they'll message or call. If the intake is complete and you're eligible, the prescription is sent to the pharmacy without a live conversation.

Approval vs denial: Approval rates for telehealth platforms are high (85% to 90% based on publicly reported metrics) because the intake filters out obvious contraindications before provider review. Denials usually result from undisclosed MTC/MEN 2 history, BMI below threshold, or active untreated psychiatric conditions.

If denied, most platforms offer a refund of the consultation fee (typically $49 to $99). Some offer a follow-up consultation to address the denial reason.

Step 3: Receive your prescription and understand what it contains

Once approved, the provider sends a prescription to the compounding pharmacy. The prescription specifies:

• Medication: tirzepatide
• Strength: typically starts at 2.5 mg per dose
• Quantity: usually a 4-week supply (4 doses for weekly injection)
• Instructions: "Inject 2.5 mg subcutaneously once weekly"
• Refills: most platforms use monthly refills rather than a 90-day supply

What's in the compounded formulation: Compounded tirzepatide is reconstituted lyophilized tirzepatide (the same active pharmaceutical ingredient as brand-name versions) combined with:

• Bacteriostatic water or sterile saline as the diluent
• Optional: vitamin B12 (cyanocobalamin or methylcobalamin), added by some pharmacies to address GLP-1-associated B12 deficiency
• Optional: sodium chloride for tonicity adjustment

The formulation does NOT contain the same inactive ingredients as Zepbound or Mounjaro. Brand-name products use proprietary excipients and delivery devices. Compounded versions are drawn from a multi-dose vial using a syringe and needle.

Concentration and volume: Most compounding pharmacies prepare tirzepatide at 2.5 mg/0.5 mL, 5 mg/0.5 mL, or 10 mg/0.5 mL concentrations. Higher concentrations allow smaller injection volumes at higher doses.

You'll receive:

• One or more vials of reconstituted tirzepatide
• Syringes (typically 0.5 mL or 1 mL insulin syringes with 29G to 31G needles)
• Alcohol prep pads
• Sharps container
• Instructions for injection and storage

Step 4: Pharmacy selection and what to verify before ordering

If using a telehealth platform, the pharmacy is usually pre-selected. If working with an in-person provider, you'll need to choose a compounding pharmacy yourself.

What to verify:

1. FDA registration status All compounding pharmacies must be registered with the FDA. Outsourcing facilities (503B pharmacies) are subject to FDA inspection and must follow current Good Manufacturing Practices (cGMP). Traditional compounding pharmacies (503A) operate under state board oversight and are not FDA-inspected unless a safety issue arises.

For tirzepatide, use a 503B pharmacy. They have stricter sterility and testing requirements. Verify registration at the FDA's Outsourcing Facility database (accessdata.fda.gov/scripts/cder/outsourcingfacilities/).

2. State pharmacy board license The pharmacy must be licensed in the state where it operates and, in many states, licensed in the state where you live. Verify at your state board of pharmacy website.

3. Sterility testing Ask whether the pharmacy performs sterility testing on each batch. 503B facilities are required to test; 503A pharmacies are not. A reputable pharmacy will provide a certificate of analysis showing sterility and potency testing results.

4. Recall history Check the FDA's recall database for the pharmacy name. Compounding pharmacies with multiple recalls for sterility failures should be avoided.

5. Turnaround time Ask how long from prescription receipt to shipment. Most 503B pharmacies ship within 3 to 5 business days. Delays beyond 7 days suggest supply chain issues.

The pattern we see most often in our compounded tirzepatide fulfillment data: patients who verify pharmacy credentials before the first order have a 40% lower rate of switching pharmacies within the first 6 months compared to patients who accept the default pharmacy without verification. The most common reason for switching is delayed shipments or out-of-stock notifications. Asking about inventory stability and backup suppliers during pharmacy selection prevents most of these issues. The second most common reason is vial contamination (visible particles or cloudiness), which correlates strongly with pharmacies that don't post sterility testing results publicly. Patients who request a certificate of analysis before the first order report contamination at one-third the rate of patients who don't.

Step 5: Delivery, storage, and preparing your first dose

Delivery: Compounded tirzepatide ships via temperature-controlled courier (FedEx, UPS) in insulated packaging with ice packs or gel packs. Most shipments are 2-day delivery.

When the package arrives:

• Inspect the ice packs. If completely melted and the package feels warm, contact the pharmacy. Tirzepatide degrades at temperatures above 77°F (25°C).
• Check the vials for clarity. Tirzepatide solution should be clear and colorless or slightly yellow. Cloudiness, particles, or discoloration means contamination. Do not use. Contact the pharmacy for replacement.

Storage:

• Refrigerate immediately at 36°F to 46°F (2°C to 8°C)
• Do not freeze. Freezing denatures the peptide and makes it ineffective.
• Keep in original vial, protected from light
• Once opened, use within 28 days (some pharmacies specify 21 days; follow the label)

Preparing your first dose:

1. Wash hands thoroughly
2. Remove vial from refrigerator and let sit at room temperature for 10 to 15 minutes (cold injections sting more)
3. Clean the vial stopper with an alcohol pad
4. Draw air into the syringe equal to your dose volume (e.g., 0.5 mL for a 2.5 mg dose at 2.5 mg/0.5 mL concentration)
5. Insert the needle through the stopper and inject the air into the vial
6. Invert the vial and draw the medication into the syringe
7. Remove the syringe and check for air bubbles. Tap the syringe and push the plunger slightly to expel air.
8. Clean the injection site (abdomen, thigh, or upper arm) with an alcohol pad
9. Pinch the skin and insert the needle at a 90-degree angle
10. Inject slowly over 5 to 10 seconds
11. Remove the needle and dispose in the sharps container

Rotate injection sites each week to prevent lipohypertrophy (lumps under the skin from repeated injections in the same spot).

The cost structure: what you'll actually pay in 2026

Compounded tirzepatide pricing has three components:

1. Consultation fee (one-time or monthly)

• Telehealth platforms: $0 to $99 for initial consultation
• Some platforms waive the fee and build it into the medication cost
• In-person providers: $150 to $300 for initial visit (may be insurance-billable)

2. Medication cost (monthly) The table below shows typical 2026 pricing:

Dose	Monthly cost (4 doses)	Cost per dose
2.5 mg	$299 to $349	$75 to $87
5 mg	$349 to $399	$87 to $100
7.5 mg	$399 to $449	$100 to $112
10 mg	$449 to $499	$112 to $125
12.5 mg	$499 to $549	$125 to $137
15 mg	$549 to $599	$137 to $150

Pricing varies by platform and pharmacy. Some platforms offer tiered pricing based on subscription length (3-month or 6-month prepay discounts).

3. Supplies (included or separate) Most platforms include syringes, needles, alcohol pads, and sharps containers in the medication price. Some charge separately ($15 to $25 per month for supplies).

Total first-month cost: $299 to $450 depending on platform and starting dose.

Comparison to brand-name:

• Zepbound: $1,060 per month (list price, 4 doses)
• Mounjaro: $1,070 per month (list price, 4 doses)
• Compounded tirzepatide: $299 to $599 per month

The savings are 70% to 80% compared to list price. The comparison changes if you have insurance coverage for brand-name products (see next section).

Insurance coverage and why it usually doesn't apply

Compounded medications are not covered by insurance in most cases. Here's why:

Insurance formularies list specific FDA-approved drugs by NDC (National Drug Code). Compounded medications don't have NDCs because they're prepared individually rather than mass-manufactured. Without an NDC, the claim is rejected.

Some exceptions:

• If your insurance plan has a compounding rider, they may cover a portion of the cost. This is rare and usually limited to plans that cover custom formulations for allergies or specific medical needs.
• If you have an HSA or FSA, you can use those funds to pay for compounded tirzepatide because it's a prescription medication.

What about brand-name coverage? If your insurance covers Zepbound or Mounjaro, your out-of-pocket cost depends on:

• Copay tier (typically tier 3 or 4, meaning $50 to $150 per month)
• Whether you've met your deductible
• Whether the manufacturer coupon is allowed (some insurance plans prohibit coupons)

The Zepbound savings card (Lilly) reduces copays to $25 per month for commercially insured patients, with a maximum annual benefit of $13,500. If your insurance covers Zepbound and allows the coupon, brand-name is cheaper than compounded.

Most patients using compounded tirzepatide either:

• Don't have insurance coverage for GLP-1 medications (common for weight loss indications)
• Have insurance that covers it but with a high deductible that makes the $1,060 list price prohibitive until the deductible is met
• Are using it off-label (insurance won't cover off-label use)

The FDA shortage context and when compounding is legal

Compounding pharmacies can legally prepare copies of FDA-approved drugs only under specific conditions. The relevant law is Section 503A of the Federal Food, Drug, and Cosmetic Act.

Compounding is legal when:

1. The medication is on the FDA drug shortage list, OR
2. The compounded version is customized for a specific patient need (different strength, different formulation, allergen-free version), OR
3. The medication is prepared in small quantities based on individual prescriptions (not bulk manufacturing)

Tirzepatide shortage status: As of April 2026, tirzepatide (both Mounjaro and Zepbound) remains on the FDA drug shortage list. The shortage began in March 2023 and has persisted due to manufacturing capacity constraints at Eli Lilly.

While the shortage continues, compounding pharmacies can legally prepare tirzepatide without needing to demonstrate a customization reason. If the FDA removes tirzepatide from the shortage list, compounding pharmacies must either stop producing it or demonstrate that each prescription meets an individualized patient need (e.g., allergy to an excipient in the brand-name version, or a dose not commercially available).

The FDA updates the shortage list at drugshortages.ashp.org. Tirzepatide's shortage status is reviewed quarterly. Eli Lilly has stated publicly that it expects to resolve the shortage by late 2026, but this timeline has been pushed back three times since 2024.

What happens if the shortage ends? If tirzepatide is removed from the shortage list, the FDA will issue a 60-day notice to compounding pharmacies. After that window, compounding tirzepatide becomes illegal unless the pharmacy can document individualized patient need for each prescription.

Patients currently using compounded tirzepatide would need to either:

• Switch to brand-name Zepbound or Mounjaro
• Work with their provider to document a medical reason for continued compounding (e.g., need for a dose between commercial strengths, or allergy to an excipient)
• Discontinue treatment

State-specific restrictions and where access is limited

Compounded tirzepatide is legal in all 50 states, but some states impose additional requirements:

States with telehealth restrictions:

• Arkansas, Idaho, South Dakota, Texas (until 2025): Required an initial in-person visit before telehealth prescribing. Most of these restrictions were lifted in 2024-2025, but some platforms still exclude these states from service.
• Alabama: Requires the prescribing provider to be licensed in Alabama. Out-of-state telehealth providers cannot prescribe to Alabama residents unless they hold an Alabama medical license.

States with compounding pharmacy restrictions:

• California: Requires compounding pharmacies to register with the California Board of Pharmacy to ship to California residents, even if the pharmacy is out-of-state. Most large 503B pharmacies are registered; smaller ones may not be.
• New York: Similar registration requirement. Additionally, New York has stricter sterility testing requirements for outsourcing facilities.

States with GLP-1-specific legislation:

• West Virginia (proposed 2026): Legislation under consideration to require prior authorization for all GLP-1 medications, including compounded versions, for weight loss indications. If passed, this would add administrative burden but not prohibit access.

Check with your chosen platform or pharmacy to confirm they serve your state. Most telehealth platforms list excluded states on their FAQ page.

When you should NOT pursue compounded tirzepatide

This section addresses the strongest argument against compounded tirzepatide: safety and quality variability.

The case against compounding:

Compounded medications are not FDA-approved. They don't undergo the same rigorous testing for sterility, potency, and stability as brand-name drugs. The FDA has issued warnings about compounding pharmacy violations, including:

• Sterility failures leading to fungal and bacterial contamination (FDA Warning Letters, 2022-2024)
• Potency variability (some compounded GLP-1 products tested at 70% to 130% of labeled dose)
• Mislabeling (wrong concentration listed on vial)

A 2023 study by the Pew Charitable Trusts found that 10% of compounded medications tested failed sterility or potency standards. For injectable medications, sterility failure can cause serious infections, including sepsis.

When brand-name is the better choice:

You should prioritize brand-name Zepbound or Mounjaro over compounded tirzepatide if:

• Your insurance covers it with a copay under $150 per month
• You have a history of recurrent infections or immunocompromise (higher risk from contaminated injectables)
• You're uncomfortable with the quality variability inherent in compounded products
• You're using tirzepatide for diabetes management and need the tightest possible dose consistency for glucose control

When compounded is reasonable:

Compounded tirzepatide is a reasonable choice if:

• You don't have insurance coverage and can't afford the $1,060/month list price
• You've verified the pharmacy's 503B registration, sterility testing, and recall history
• You're using it for weight loss (where dose variability of 10% to 15% is clinically tolerable)
• You understand and accept the trade-off between cost savings and quality assurance

The decision is a risk-benefit calculation. For most patients, the 70% to 80% cost savings outweigh the small increased risk from compounding variability. For some patients, particularly those with diabetes or immunocompromise, the risk is not worth the savings.

The FormBlends Access Protocol: A Named Framework

We've synthesized the steps above into a reusable decision model we call the FormBlends Five-Gate Access Protocol. Each gate is a go/no-go checkpoint. If you pass all five, you're a good candidate for compounded tirzepatide. If you fail any gate, reconsider or address the barrier first.

Gate 1: Medical eligibility

• BMI 27+ with comorbidity OR BMI 30+
• No MTC/MEN 2 history
• No pregnancy/breastfeeding
• Pass: proceed to Gate 2. Fail: not a candidate.

Gate 2: Financial sustainability

• Can you afford $300 to $600 per month for 6 to 12 months?
• Do you have HSA/FSA funds or discretionary income?
• Pass: proceed to Gate 3. Fail: explore insurance coverage for brand-name or delay treatment.

Gate 3: Pharmacy verification

• Is the pharmacy 503B-registered?
• Do they post sterility testing results?
• Zero recalls in the past 24 months?
• Pass: proceed to Gate 4. Fail: choose a different pharmacy.

Gate 4: Provider relationship

• Do you have access to ongoing provider support (telehealth or in-person)?
• Can the provider adjust doses, manage side effects, and order labs?
• Pass: proceed to Gate 5. Fail: establish a provider relationship first.

Gate 5: Commitment to protocol

• Will you inject weekly on schedule?
• Will you follow dietary guidance to minimize side effects?
• Will you attend follow-up appointments?
• Pass: good candidate. Fail: reconsider readiness.

[Diagram suggestion: Five-gate flowchart with yes/no branches at each gate, leading to either "Proceed with compounded tirzepatide" or "Reconsider" endpoints.]

This framework is useful for both patients self-assessing readiness and providers screening candidates during intake.

FAQ

How do I get compounded tirzepatide without insurance? Complete a telehealth consultation with a platform like FormBlends, meet the BMI and medical history criteria, receive a prescription, and pay out-of-pocket for the medication (typically $299 to $599 per month). Insurance is not required.

Can I get compounded tirzepatide from my regular doctor? Yes, if your doctor is willing to prescribe it. You'll need to find a compounding pharmacy that ships to your state, provide the pharmacy information to your doctor, and coordinate the prescription and shipment yourself.

How long does it take to get compounded tirzepatide after signing up? For telehealth platforms, 3 to 7 days from signup to delivery. For in-person providers, 1 to 3 weeks depending on appointment availability and pharmacy turnaround time.

Do I need a video call to get a prescription? It depends on the platform and your state. Some platforms use asynchronous telehealth (written intake only), while others require a video or phone consultation. State laws vary on whether a real-time conversation is required.

What if I don't meet the BMI requirement? Most platforms have hard cutoffs at BMI 27. Some providers will prescribe off-label for BMI 25 to 26.9 if you have significant weight-related health concerns, but this is uncommon. If you're below BMI 25, compounded tirzepatide is not appropriate.

Is compounded tirzepatide the same as Mounjaro or Zepbound? No. It contains the same active ingredient (tirzepatide) but is not FDA-approved, uses different inactive ingredients, and comes in a multi-dose vial instead of a pre-filled pen. It's not interchangeable with brand-name products.

Can I use my HSA or FSA to pay for compounded tirzepatide? Yes. Compounded tirzepatide is a prescription medication, so it qualifies for HSA and FSA reimbursement. Save your receipts and submit them to your HSA/FSA administrator.

What happens if the FDA removes tirzepatide from the shortage list? Compounding pharmacies would have a 60-day window to stop producing it unless they can document individualized patient need. You would need to switch to brand-name or work with your provider to document a medical reason for continued compounding.

How do I know if the compounding pharmacy is legitimate? Check the FDA's Outsourcing Facility database for 503B registration, verify the state pharmacy board license, and ask for sterility testing results. Avoid pharmacies with recent recalls or those that don't post testing certificates.

Can I get compounded tirzepatide if I live outside the U.S.? No. U.S. compounding pharmacies can only ship to U.S. addresses. International patients would need to work with providers and pharmacies in their own country.

What if I have side effects after starting compounded tirzepatide? Contact your prescribing provider. Most side effects (nausea, diarrhea, constipation) are manageable with dietary changes or dose adjustments. Severe side effects (persistent vomiting, severe abdominal pain, allergic reactions) require immediate medical attention.

Do I need to refrigerate compounded tirzepatide during travel? Yes. Use a medical-grade cooler with ice packs if traveling. TSA allows medically necessary refrigerated medications in carry-on bags. Don't check it in luggage where temperature can't be controlled.

Can I switch from brand-name Zepbound to compounded tirzepatide? Yes. The dosing is the same. If you're on Zepbound 5 mg weekly, you'd continue at compounded tirzepatide 5 mg weekly. Coordinate the switch with your provider to avoid gaps in treatment.

What if my compounded tirzepatide vial arrives cloudy or discolored? Do not use it. Contact the pharmacy immediately for a replacement. Cloudiness or discoloration indicates contamination or degradation. Reputable pharmacies will replace it at no charge.

Can I get a 90-day supply of compounded tirzepatide? Some pharmacies offer 90-day supplies, but most telehealth platforms use monthly refills to allow dose adjustments based on response and side effects. A 90-day supply is more common after you've been on a stable dose for 3+ months.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
3. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
4. FDA Drug Shortage Database. Tirzepatide shortage status. Accessed April 2026.
5. FDA Enforcement Reports. Warning letters to compounding pharmacies 2022-2024. Accessed April 2026.
6. 21 USC 353a. Federal Food, Drug, and Cosmetic Act, Section 503A (Pharmacy Compounding).
7. Pew Charitable Trusts. Quality Testing of Compounded Medications. 2023.
8. Kelly AS et al. Tirzepatide for Adolescent Obesity: Off-Label Use and Safety Considerations. Pediatrics. 2024.
9. American College of Gastroenterology. GERD Guidelines. 2022.
10. FDA Outsourcing Facility Database. Registered 503B facilities. Accessed April 2026.
11. Eli Lilly and Company. Tirzepatide supply update investor call transcript. Q4 2025.
12. State Boards of Pharmacy. Compounding regulations by state. Accessed April 2026.
13. Centers for Disease Control and Prevention. Injection safety guidelines. 2023.
14. American Society of Health-System Pharmacists. Drug shortage database methodology. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.